For research teamsHelp me find a study
Back to all studies
Enrolling By InvitationNCT07095465

52-Week, Extension Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)

This study is enrolling by invitation in the United States, in France, in Bulgaria, .... It is testing ACP-204 for Lewy Body Dementia Psychosis.

SchizophreniaDrugFrom 55 Years to 84 Years

The public registry lists enrollment by invitation. This is not open recruitment; contact the research team to understand who may be invited.

Explore recruiting studies on this topic

Then choose your country and confirm availability with each study site.

In plain English

Key information made simple

What is this study testing?

This study is testing whether ACP-204 may be useful for adults experiencing schizophrenia.

What would participation involve?

Participants may receive ACP-204, attend study visits with the research team. The registry lists locations in Bulgaria, in Czechia, and in France.

Who is it mainly for?

This study appears to be mainly for adults with schizophrenia.

What should you check before joining?

Ask about the dose, safety monitoring, and possible side effects, whether there is a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.

Your next step

Check the study details

Check the official source, then confirm these points with the research team.

View official study record (opens in a new tab)

  • Recruitment and eligibility

    Is a site open, and who can take part?

  • Visits and time

    Where are visits, can any be remote, and how much time is needed?

  • Costs and support

    What costs, reimbursement or compensation apply?

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateStarted: November 14, 2025
Recruitment status
Enrolling By Invitation
Enrollment listed in the registry
126
Sponsor
ACADIA Pharmaceuticals Inc.
Sponsor type
Other organization
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States, France, Bulgaria, ...
Age range
From 55 Years to 84 Years
Official registry ID
NCT07095465
Official title
52-Week, Phase 3, Open-Label Extension Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)

Check recruitment and locations

Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.

View official study record (opens in a new tab)

The overall study status can differ from each site's status. Open a country to see its locations and their registry status.

Bulgaria · 3 sites
  • Ambulatory for Individual Practice for Specialized Medical Care in Psychiatry - Dr Ivo Natsov
    Cherven Bryag
    Site status: Not listed — confirm with the team
  • DCC "Sv. Vrach and Sv. Sv. Kuzma and Damyan", OOD
    Sofia
    Site status: Not listed — confirm with the team
  • DCC Mladost M- Varna, OOD
    Varna
    Site status: Not listed — confirm with the team
Czechia · 3 sites
  • Fakultni Nemocnice u sv. Anny v Brne
    Brno
    Site status: Not listed — confirm with the team
  • NEUROHK s.r.o. Poliklinika Chocen a.s.
    Choceň
    Site status: Not listed — confirm with the team
  • Vestra Clinics s.r.o
    Rychnov nad Kněžnou
    Site status: Not listed — confirm with the team
France · 3 sites
  • CHU Tours- Hopital Bretonneau
    Tours, Cedex 9
    Site status: Not listed — confirm with the team
  • Hopital Neurologique Bron
    Bron, Rhone
    Site status: Not listed — confirm with the team
  • CHU Strasbourg-Hopital Hautepierre
    Strasbourg
    Site status: Not listed — confirm with the team
Italy · 3 sites
  • Azienda Ospedaliera Univerrsitaria
    Naples, Napoli
    Site status: Not listed — confirm with the team
  • Università Campus Bio-Medico di Roma
    Roma, Roma
    Site status: Not listed — confirm with the team
  • Azienda Ospedaliera Universitaria Policlinico Umberto I - Università di Roma La Sapienza, UOI Day Hospital di Neurologia
    Roma, Roma
    Site status: Not listed — confirm with the team
Serbia · 1 site
  • Institute of Mental Health
    Belgrade
    Site status: Not listed — confirm with the team
United States · 17 sites
  • ATP Clinical Research Inc.
    Irvine, California
    Site status: Not listed — confirm with the team
  • Humanity Clinical Research, Corp
    Aventura, Florida
    Site status: Not listed — confirm with the team
  • Parkinson's Disease and Movement Disorders Center of Boca Raton
    Boca Raton, Florida
    Site status: Not listed — confirm with the team
  • K2 Summit Research
    Lady Lake, Florida
    Site status: Not listed — confirm with the team
  • Homestead Associates in Research Inc
    Miami, Florida
    Site status: Not listed — confirm with the team
  • Advanced Clinical Research Network, Corp
    Miami, Florida
    Site status: Not listed — confirm with the team
  • MediClear Medical & Research Center, Inc.
    Miami, Florida
    Site status: Not listed — confirm with the team
  • Health Synergy Clinical Research, LLC
    West Palm Beach, Florida
    Site status: Not listed — confirm with the team
  • Hawaii Pacific Neuroscience
    Honolulu, Hawaii
    Site status: Not listed — confirm with the team
  • University of Kansas Medical Center Research Institute Inc.
    Kansas City, Kansas
    Site status: Not listed — confirm with the team
  • Parkinson's Disease and Movement Disorders Center of Boca Raton d/b/a Parkinson's Research Center of America-Long Island
    Commack, New York
    Site status: Not listed — confirm with the team
  • The Ohio State University, Energy Advancement and Innovation Center
    Columbus, Ohio
    Site status: Not listed — confirm with the team
  • The Movement Disorder Clinic of Oklahoma
    Tulsa, Oklahoma
    Site status: Not listed — confirm with the team
  • Horizon Clinical Research Group
    Cypress, Texas
    Site status: Not listed — confirm with the team
  • R and H Clinical Research
    Stafford, Texas
    Site status: Not listed — confirm with the team
  • Virginia Commonwealth University (a public institution of higher education)
    Richmond, Virginia
    Site status: Not listed — confirm with the team
  • EvergreenHealth
    Kirkland, Washington
    Site status: Not listed — confirm with the team

Ask HopeStage to help me review this study

This record does not confirm open recruitment. We can help you understand it and explore other studies.

Loading the security check...
Study ID: NCT07095465. We help you review the study, but cannot decide medical eligibility.
In practice

For you

Participation may contribute to research. Personal benefit is not guaranteed.

Ask the research team to explain the activities, time commitment, and follow-up involved.

Study sites are listed. Confirm the relevant site and any travel before making plans.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What is this study trying to understand?

This study is exploring medication or study treatment for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.

Does this study involve a medication?

This appears to be a medication / drug study involving ACP-204. Phase 3 studies are usually larger and aim to confirm effectiveness and safety in a broader group.

Who might this study be for?

This study may concern people with schizophrenia; age range: From 55 Years to 84 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.

What would I likely need to do?

You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

What side effects, interactions, or treatment changes should I check?

If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.

Will I need to travel or attend in-person visits?

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

Who is behind this study?

This study is sponsored by ACADIA Pharmaceuticals Inc., which appears to be another type of organization. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

Can I still join this study?

The public registry lists enrollment by invitation. This is not open recruitment; contact the research team to understand who may be invited.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me
Related studies

Explore related studies

Other studies that may be relevant based on condition, country, or study type.